Sellas Life Sciences Stock Surges 12% Ahead of Key Clinical Trial Results and Takeover Speculation
Sellas Life Sciences (SLS) shares rose 12.26% to close at $13.19 on July 17, 2026, as investors positioned for a potentially company-defining phase 3 clinical trial readout for its Galinpepimut-S (GPS) treatment in acute myeloid leukemia. The trial is expected to report data once it reaches the 80th patient death, with the company reporting 78 deaths in its latest update. Investor enthusiasm was further fueled by takeover speculation after the company amended executive severance agreements with three top executives, including CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic, providing lump-sum payments in case of a change of control. Additionally, institutional interest grew significantly, with hedge fund stakes more than doubling to 13 funds in Q1 2026, holding $13.49 million in shares, up from $10.8 million in Q4 2025.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection